Patent Details
| Patent # | Title | Assignee | Expires | Status |
|---|---|---|---|---|
| 8399514 | Orange Book listed patent | Biogen Inc. | Feb 7, 2028 | 1.6y left |
| 10391160 | Orange Book listed patent | Biogen Inc. | Mar 13, 2035 | 8.7y left |
| 10555993 | Orange Book listed patent | Biogen Inc. | Mar 13, 2035 | 8.7y left |
| 10994003 | Orange Book listed patent | Biogen Inc. | Mar 13, 2035 | 8.7y left |
| 10959972 | Orange Book listed patent | Biogen Inc. | Nov 16, 2035 | 9.4y left |
| 11129806 | Orange Book listed patent | Biogen Inc. | Nov 16, 2035 | 9.4y left |
| 11007166 | Orange Book listed patent | Biogen Inc. | Nov 16, 2035 | 9.4y left |
| 11007167 | Orange Book listed patent | Biogen Inc. | Nov 16, 2035 | 9.4y left |
| 11246850 | Orange Book listed patent | Biogen Inc. | Nov 16, 2035 | 9.4y left |
Related Drug Patent Expirations
0 patents · Genentech Inc.
22 patents · earliest expires 2028 · Pfizer Inc.
2 patents · earliest expires 2027 · Bristol-Myers Squibb Company
6 patents · earliest expires 2027 · Novartis AG
3 patents · earliest expires 2027 · Pfizer Inc.
44 patents · earliest expires 2027 · Pharmacyclics LLC
For Tecfidera, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for Tecfidera is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.